Clinical Practice

Real talk about psychopharmacology, clinical confidence, and building a practice you love — from Lindsay and the Fellowship faculty.

Editorial still-life of a small unbranded plain glass medical vial with a smooth metallic crimp top standing upright on a quiet pale clinical countertop representing a long-acting injectable antipsychotic formulation, a small unbranded plain disposable syringe with a sheathed needle resting flat horizontally beside the vial representing the injection itself, a small shallow round amber-tinted glass dish to the side holding three small smooth round white tablets representing the tapering oral antipsychotic overlap, a small simple sealed brushed-metal sharps container in the background representing safe injection practice, and a small ruled cream paper notepad in the foreground with a thin black fountain pen resting diagonally across it representing the PMHNP transition protocol notes — header illustration for a 2026 PMHNP clinical-practice guide on switching patients from oral antipsychotics to long-acting injectables.

Clinical Practice

LAI Antipsychotics: 2026 PMHNP Transition Protocol

PMHNP step-by-step protocol for switching oral antipsychotics to long-acting injectables in 2026: aripiprazole, paliperidone, risperidone overlap.

June 2, 2026 Read More →

Editorial still-life of a small smooth empty amber prescription bottle standing upright on a quiet wooden bedside table at evening representing prazosin prescribed for PTSD nightmares, a small simple analog desk clock viewed from the front showing late evening hours representing bedtime dosing, a soft folded woven cream wool blanket draped lightly across one corner of the table representing restorative sleep, a small bedside reading lamp casting a warm focused circle of light from above creating a calm pool of light on the table, and a small closed ruled cream paper sleep journal with a thin black fountain pen resting diagonally across it representing nightmare-frequency tracking — header illustration for a 2026 PMHNP clinical guide on the prazosin titration protocol for PTSD-related nightmares.

Clinical Practice

Prazosin for PTSD Nightmares: 2026 PMHNP Titration Protocol

85% of patients on prazosin for PTSD nightmares are underdosed. The 2026 PMHNP titration ladder, sex-specific target doses, and orthostatic safety floor.

May 22, 2026 Read More →

Editorial still-life of a small wooden chair viewed from the side with a smooth river stone resting on its seat representing the inability to sit still, a small analog pocket watch with a thin chain resting beside the chair representing the slow ticking time patients feel during akathisia, a small unmarked closed manila chart folder resting flat behind the chair, and a ceramic mug of warm tea with gentle steam on a quiet wooden desk in soft natural side light — header illustration for a 2026 PMHNP clinical-practice decision tree on antipsychotic-induced akathisia management.

Clinical Practice

Akathisia Management: 2026 PMHNP Decision Tree

Akathisia gets misread as anxiety in up to half of cases. The 2026 PMHNP decision tree: BARS scoring, mirtazapine vs. propranolol, what to never miss.

May 19, 2026 Read More →

Editorial still-life of a stylized abstract ECG strip with subtle smooth curved peaks drawn on cream paper resting flat in the foreground, a small smooth silver stethoscope coiled neatly to the side, a small simple analog stopwatch resting beside the ECG strip representing the precise timing of the QT interval, a small unmarked closed manila chart folder beneath the strip, and a ceramic mug of warm tea with gentle steam on a quiet wooden desk in soft natural side light — header illustration for a 2026 PMHNP clinical-practice protocol on QTc monitoring for psychotropic medications.

Clinical Practice

QTc Monitoring for Psychotropics: 2026 PMHNP Protocol

A QTc above 500 ms triples the risk of torsades. Here's the 2026 PMHNP protocol for screening, monitoring, and acting on psychotropic-driven QT prolongation.

May 18, 2026 Read More →

Editorial still-life of a small ceramic anatomical brain sculpture with two softly glowing accent points suggesting two distinct receptor targets, a small unlabeled amber medicine bottle with a few capsules beside it, an upright fountain pen across a closed manila folder, and a ceramic mug of herbal tea with gentle steam on a quiet wooden desk in soft natural side light — header illustration for a 2026 PMHNP prescribing guide to Cobenfy (xanomeline-trospium), the first new-mechanism antipsychotic for schizophrenia in decades.

Clinical Practice

Cobenfy for Schizophrenia: A 2026 PMHNP Prescribing Guide

Cobenfy is the first schizophrenia drug that skips D2 blockade entirely. Here is how PMHNPs dose, titrate, and monitor xanomeline-trospium safely in 2026.

May 15, 2026 Read More →

Editorial still-life of six small amber medicine bottles arranged in a smooth hyperbolic descending arc on a quiet wooden desk beside a glass dropper bottle of liquid medicine, a folded prescription pad, and a fountain pen in soft natural side light — header illustration for a 2026 PMHNP clinical practice article on hyperbolic antidepressant tapering protocols.

Clinical Practice

Hyperbolic Antidepressant Tapering: 2026 PMHNP Protocol

Hyperbolic antidepressant tapering — the 10% rule, liquid formulations, the 4-week step. The 2026 PMHNP protocol that actually prevents withdrawal.

May 12, 2026 Read More →

Clinical Practice

Tardive Dyskinesia: A 2026 PMHNP Screening Playbook

Tardive dyskinesia hits 1 in 5 long-term antipsychotic patients. Here is the 2026 PMHNP playbook for AIMS screening, risk stratification, and VMAT2 prescribing.

May 7, 2026 Read More →

Editorial still-life of a single GLP-1 injection pen lying horizontally beside a small empty pill bottle and a softly tilted balance scale — illustration for a 2026 PMHNP guide to GLP-1 receptor agonists for antipsychotic-induced weight gain.

Clinical Practice

GLP-1s for Antipsychotic Weight Gain: 2026 PMHNP Guide

Semaglutide cut 19 lbs and HbA1c 0.25% in patients on clozapine and olanzapine. Here is how PMHNPs use GLP-1s for antipsychotic weight gain in 2026.

May 5, 2026 Read More →

Minimalist apothecary scale balancing a medication tablet against a brain silhouette — editorial still-life illustrating BPD prescribing decisions for PMHNPs.

Clinical Practice

BPD Prescribing: A PMHNP Reality Check for 2026

The APA's 2024 borderline personality guideline says no drug treats the core illness. Here is what PMHNPs should actually prescribe and avoid.

April 23, 2026 Read More →

Abstract branching decision pathway diverging into four stylized capsule forms with a contrasting mood wave motif, cream burgundy and coral palette — bipolar depression PMHNP treatment algorithm header

Clinical Practice

Bipolar Depression: The 2026 PMHNP Treatment Algorithm

Bipolar depression demands a different algorithm than MDD. Here are the 2026 first-line options every PMHNP should have memorized — and the trap to avoid.

April 23, 2026 Read More →

Clinical Practice

Join the Fellowship today.